¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"residual immunity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • sterilizing immunity
    ºÒÀӸ鿪
  • functional residual air
    ±â´ÉÀûÀܱâ
  • functional residual capacity
    ±â´ÉÀܱâ¿ë·®
  • residual
    1. ÀÜ·ù- 2. ÀÜ¿©-, ÀÜÁ¸- 3. ÈÄÀ¯-
  • residual abscess
    ÀÜ·ù°í¸§Áý, ÀÜ·ù³ó¾ç
  • residual accommodation
    ÀÜ¿©Á¶Àý
  • residual antigen
    ÀÜ·ùÇ׿ø
  • residual astigmatism
    ÀÜÁ¸³­½Ã
  • residual chlorine
    ÀÜ·ù¿°¼Ò
  • residual chromatin
    ÀÜ¿©¿°»öÁú
  • residual current
    ÀÜ·ùÀü·ù
  • residual cyst
    ÀÜ·ù³¶
  • residual free chlorine
    ÀÜ·ùÀ¯¸®¿°¼Ò
  • residual hearing
    ÀÜû
  • residual latency
    ÀÜ·ùÀẹ, ÀÜ·ùÀá½Ã
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • sterilizing immunity
    ºÒÀӸ鿪
  • transplacental immunity
    ŹݰæÀ¯¸é¿ª
  • transplantation immunity
    À̽ĸ鿪
  • functional residual air
    ±â´ÉÀûÀܱâ
  • residual abscess
    ÀÜ·ù°í¸§Áý, ÀÜ·ù³ó¾ç
  • residual accommodation
    ÀÜ¿©Á¶Àý
  • residual antigen
    ÀÜ¿©Ç׿ø
  • residual astigmatism
    ÀÜ¿©³­½Ã
  • coherent residual transverse magnetization
    °áÁýÀÜ·ù°¡·ÎÃàÀÚ±âÈ­
  • functional residual capacity
    ±â´ÉÀûÀܱâ¿ë·®
  • residual carbon
    ÀÜ¿©Åº¼Ò
  • residual chlorine
    ÀÜ·ù¿°¼Ò
  • residual chromatin
    ÀÜ¿©¿°»öÁú
  • residual current
    ÀÜ·ùÀü·ù
  • residual cyst
    ÀÜ·ù³¶
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • immunity, nonspecific
    ºñƯÀ̸鿪
  • immunity, passive
    ¼öµ¿¸é¿ª
  • immunity, protective
    ¹æ¾î¸é¿ª
  • immunity, specific
    ƯÀ̸鿪
  • immunity, tissue
    Á¶Á÷¸é¿ª
  • immunity, transplantation
    À̽ĸ鿪
  • immunity,cell-mediated
    ¼¼Æ÷¸Å°³¼º(á¬øàØÚË¿àõ)
  • immunity,humoral
    ü¾×¼º
  • impaired cellular immunity
    ¼¼Æ÷¼º ¸é¿ªºÎÀü(á¬øààõØóæ¹ÝÕîï).
  • inborn immunity
    ¼±Ãµ(¼º) ¸é¿ª.
  • individual immunity
    °³Ã¼¸é¿ª.
  • infection immunity
    °¨¿°¸é¿ª.
  • innate immunity
    ÀÚ¿¬¸é¿ª(í»æÔØóæ¹), ¼±Ãµ¸é¿ª(à»ô¸Øóæ¹).
  • peroral immunity
    °æ±¸¸é¿ª(¡­Øóæ¹).
  • protective immunity
    ¹æ¾î¸é¿ª
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • residual epilepsy
    ÀÜ·ù°£Áú(íÑë§ÊÖòð).
  • residual epilepsy
    ÀÜ·ù°£Áú(íÑë§ÊÖòð)
  • residual free chlorine
    À¯¸®ÀÜ·ù¿°¼Ò(·®)(ËôËöËöËôËçËÛ).
  • residual hearing
    ÀÜû
  • residual lumen
    ÀÜ¿©³»°­
  • residual nitrogen
    ÀÜ¿©Áú¼Ò(íÑæ®òòáÈ).
  • residual nucleus
    ÀÜ·ù(»ý¼º)ÇÙ(íÑë§ ßæà÷ú·).
  • residual paralysis
    ÈÄ(À¯)¸¶ºñ.
  • residual poliomyelitis
    ¼Ò¾Æ¸¶ºñÈÄÀ¯Áõ.
  • residual poliomyelitis
    ¼Ò¾Æ¸¶ºñÈÄÀ¯Áõ(á³ä®Ø«Ýöý­ë¶ñø)
  • residual proteinuria
    ÀÜÀç(¼º) ´Ü¹é´¢(íÑî¤àõÓ±ÛÜèñ).
  • residual proteinuria
    ÀÜÀç(¼º) ´Ü¹é´¢(íÑî¤àõÓ±ÛÜèñ)
  • residual pulp
    Àܼö(íÑâÐ).
  • residual quotient
    ÀܱâÀ²(íÑѨëÒ).
  • residual radiation
    ÀÜ·ù¹æ»ç¼±
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
FRC Federal Radiation Council; frozen red cells; functional reserve capacity; functional residual capaci...
FRV full-length retroviral [sequence]; functional residual volume
MRD maximum rate of depolarization; measles-rindenpest-distemper [virus group]; medical records departme...
PFRC predicted functional residual capacity
PImax maximum inspiratory pressure at residual volume
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 3
PVR post-void residual volume
RD residual disease
RF residual fraction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • natural immunity
    ÀÚ¿¬ ¸é¿ª
  • phagocytic immunity
    ½Ä¼¼Æ÷¼º ¸é¿ª
  • racial immunity
    ¹ÎÁ· ¸é¿ª
    À¯ÀüÀûÀ¸·Î °áÁ¤µÇ¾î ÀÖ´Â ÀúÇ×¼ºÀ¸·Î, ¾î¶² Á¾Á· ¸ðµÎ ¶Ç´Â °ÅÀÇ ÀüºÎ°¡ ¾î¶² Á¾·ùÀÇ °£¿°¿¡ ´ëÇÏ¿© ³ªÅ¸³ª´Â ¸é¿ª »óÅÂ.
  • specific humoral immunity
    ƯÀ̼º ü¾× ¸é¿ª
  • transplantation immunity
    ÀÌ½Ä ¸é¿ª
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
maternal immunity <epidemiology> Immunity for a neonate provided by IgG antibody generated by a mother and passed across the placenta to the unborn offspring. This provides short lived protection (with a typical half life of 3-6 months) to the neonate. Also known as immunity.
(05 Dec 1998)
passive immunity <immunology> Immunity acquired by the transfer from another animal of antibody or sensitised lymphocytes. Passive transfer of antibody from mother to offspring is important for immune defense during the perinatal period.
(18 Nov 1997)
relative immunity A modified, not completely effective resistance that results when there is a sort of "fluctuating equilibrium" between the defense mechanisms of the host and the infective agent.
(05 Mar 2000)
cell-mediated immunity <immunology> Immune response that involves effector T lymphocytes and not the production of humoral antibody.
Responsible for allograft rejection, delayed hypersensitivity and in defence against viral infection and intracellular protozoan parasites.
(26 Mar 1998)
cellular immunity <cell biology, immunology> Immune response that involves enhanced activity by phagocytic cells and does not imply lymphocyte involvement. Since the term is easily confused with cell-mediated immunity its use in this sense should be avoided.
(26 Mar 1998)
cellular immunity deficiency syndrome <syndrome> A syndrome marked by increased susceptibility to infection, especially to viral infection, associated with defective functioning of the mechanism responsible for acquired immunity of the cell-mediated kind.
See: immunodeficiency.
(05 Mar 2000)
group immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
concomitant immunity The paradoxical immune status in which resistance to reinfection coincides with the persistence of the original infection.
Synonym: concomitant immunity.
(05 Mar 2000)
herd immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
humoral immunity <immunology> A form of immunity whereby B lymphocytes and plasma cells produce antibodies to foreign agents (antigens) and stimulate T lymphocytes to attack them (cellular immunity).
These antibodies also stimulate the release of chemical mediators (for example interferon, complement) which enhance antigen destruction.
(06 Mar 1998)
specific active immunity See: acquired immunity.
(05 Mar 2000)
specific immunity The immune status in which there is an altered reactivity directed solely against the antigenic determinants (infectious agent or other) that stimulated it.
See: acquired immunity.
(05 Mar 2000)
specific passive immunity See: acquired immunity.
(05 Mar 2000)
natural immunity This includes local barriers to infection such as skin, stomach acid, mucous, the cough reflex, enzymes in tears and saliva and skin oils.
(27 Sep 1997)
natural passive immunity Immunity conferred by the mother on the foetus or newborn.
(14 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á